{"nctId":"NCT02604017","briefTitle":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection","startDateStruct":{"date":"2015-10"},"conditions":["Chronic Hepatitis C","Hepatitis C Virus","HCV"],"count":703,"armGroups":[{"label":"ABT-493/ABT-530 for 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]},{"label":"ABT-493/ABT-530 for 8 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]}],"interventions":[{"name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, at least 18 years of age at time of screening.\n* Screening laboratory result indicating hepatitis C virus (HCV) genotype 1 (GT1) infection.\n* Chronic HCV infection.\n* Subject must be HCV treatment-naïve (i.e., patient has never received a single dose of any approved or investigational regimen) or treatment-experienced (has failed prior interferon \\[IFN\\] or pegylated IFN (pegIFN) with or without ribivarin (RBV), or sofosbuvir (SOF) plus RBV with or without pegIFN therapy).\n* Subjects must be non-cirrhotic.\n\nAdditional Inclusion Criteria for HCV GT1/human immununovirus type 1 (HIV-1) co-infected patients:\n\n* HIV-1 antiretroviral treatment (ART) naïve with CD4 ≥ 500 cells/mm3 (or CD4+ % ≥ 29%) at Screening and plasma HIV-1 RNA \\<1,000 copies/mL at Screening and at least once during the 12 months prior to Screening.\n\nOR\n\n* On a stable, qualifying HIV-1 ART regimen for at least 8 weeks prior to screening, with CD4 ≥ 200 cells/mm3 (or CD4+ % ≥14%) at Screening and plasma HIV-1 RNA \\< LLOQ at Screening and at least once during the 12 months prior to Screening.\n\nExclusion Criteria:\n\n* History of severe, life-threatening or other significant sensitivity to any excipients of the study drugs.\n* Female who is pregnant, planning to become pregnant during the study or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.\n* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.\n* Positive test result at Screening for hepatitis B surface antigen (HBsAg).\n* HCV genotype performed during screening indicating co-infection with more than one HCV genotype.\n* Chronic HIV type 2 (HIV-2) infection.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Mono-infected Hepatitis C Virus Genotype 1 (HCV GT1), Direct-acting Antiviral Agent (DAA) Naïve Participants in the 12-Week Treatment Arm","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug. The primary efficacy endpoint was noninferiority of the percentage of participants who achieved SVR12 in the 12-week treatment group compared with the historical control rate for HCV GT1 subjects who are treatment-naïve or treated with pegylated-interferon alfa-2a or alfa-2b and ribavirin (pegIFN/RBV).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With SVR12: Noninferiority of 8-Week Arm to 12-Week Arm in Mono-infected HCV GT1, DAA-Naïve Participants, Excluding Those Who Discontinued/Experienced Virologic Failure by Week 8 or Had No HCV RNA Value at Week 12 or Later","description":"SVR12 was defined as plasma HCV RNA level \\<LLOQ 12 weeks after the last dose of study drug. The primary efficacy endpoint was noninferiority of the percentage of mono-infected HCV GT1, DAA-naïve participants (excluding those who discontinued/experienced virologic failure by Week 8 or had no HCV RNA value at Week 12 or later) who achieved SVR12 in the 8-week treatment arm compared with the 12-week treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With SVR12: Noninferiority of 8-Week Treatment Arm to 12-Week Treatment Arm in Mono-infected HCV GT1, DAA-Naïve Participants","description":"SVR12 was defined as plasma HCV RNA level \\<LLOQ 12 weeks after the last dose of study drug. The primary efficacy endpoint was noninferiority of the percentage of mono-infected HCV GT1, DAA-naïve participants who achieved SVR12 in the 8-week treatment arm compared with the 12-week treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12 in Mono-infected HCV GT1 Participants","description":"SVR12 was defined as plasma HCV RNA level \\<LLOQ 12 weeks after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12","description":"SVR12 was defined as plasma HCV RNA level \\<LLOQ 12 weeks after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12 in Co-infected HCV GT1/Human Immunodeficiency Virus Type 1 (HIV-1) Participants","description":"SVR12 was defined as plasma HCV RNA level \\<LLOQ 12 weeks after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12 in HCV GT1-infected, Prior Sofosbuvir (SOF) Treatment-Experienced Participants","description":"SVR12 was defined as plasma HCV RNA level \\<LLOQ 12 weeks after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as confirmed increase of \\>1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment; confirmed HCV RNA ≥100 IU/mL after HCV RNA \\<LLOQ during treatment, or HCV RNA ≥LLOQ at end of treatment with at least 6 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure in Mono-infected HCV GT1, DAA-Naïve Participants","description":"On-treatment virologic failure was defined as confirmed increase of \\>1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment; confirmed HCV RNA ≥100 IU/mL after HCV RNA \\<LLOQ during treatment, or HCV RNA ≥LLOQ at end of treatment with at least 6 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \\<LLOQ at the end of treatment, excluding reinfection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse in Mono-infected HCV GT1, DAA-Naïve Participants","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \\<LLOQ at the end of treatment, excluding reinfection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":352},"commonTop":["HEADACHE","FATIGUE","NASOPHARYNGITIS","NAUSEA","PRURITUS"]}}}